Xamoterol

Xamoterol is a cardiac stimulant that acts on beta-1 adrenergic receptors. It was developed by Allen & Hanburys and first marketed in 1988. Xamoterol has a unique mechanism of action, known as partial agonism. This means it can both stimulate and block beta-1 adrenergic receptors, depending on the circumstances.

Pharmacology

Xamoterol, chemically known as 5-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-3,4-dihydro-2(1H)-quinolinone, is a beta-1 adrenergic receptor partial agonist. This means it can both stimulate and block these receptors, depending on the circumstances. This unique mechanism of action allows it to increase cardiac output without significantly increasing heart rate or blood pressure.

Clinical Use

Xamoterol was developed for the treatment of heart failure. It was first marketed in 1988 by Allen & Hanburys, a British pharmaceutical company. However, it was withdrawn from the market in 1990 due to concerns about its safety and efficacy.

Side Effects

Like other cardiac stimulants, xamoterol can cause a range of side effects. These may include palpitations, tachycardia, angina pectoris, and arrhythmia. In some cases, these side effects can be severe and may require medical attention.

See Also

• Beta-1 adrenergic receptor
• Cardiac stimulant
• Heart failure

References

<references />